Articles Tagged With: fidaxomicin
-
Fidaxomicin vs. Oral Vancomycin for Clostridioides difficile Infection in Patients Receiving Concomitant Antibiotics
This open-label, randomized trial of patients with Clostridioides difficile infection receiving concomitant antibiotics found no difference in clinical cure between fidaxomicin and oral vancomycin.
-
Successful Post-Discharge Completion of Fidaxomicin Therapy Without Financial Toxicity
Post-discharge completion of fidaxomicin therapy was achieved for most patients with multidisciplinary proactive intervention.
-
Clostridioides difficile Infection: Guideline Update
Fidaxomicin is preferred over vancomycin for initial and recurrent cases. Bezlotoxumab is recommended in many cases of recurrent infection and initial infection in patients at high risk of recurrence.
-
Is Fecal Microbiota Transplantation Superior to Fidaxomicin for Recurrent Clostridioides difficile Infection?
In a randomized clinical trial, researchers found the combination of oral vancomycin followed by fecal microbiota transplantation was superior to treatment with fidaxomicin or vancomycin alone for patients with recurrent Clostridioides difficile infection.
-
Oral Vancomycin Is the Most Cost-effective Treatment for the First Recurrence of Clostridium Difficile Infection
The authors of a pharmacoeconomic study comparing bezlotoxumab plus oral vancomycin, oral vancomycin alone, and fidaxomicin found that oral vancomycin alone was the most cost-effective regimen to treat the first recurrence of Clostridium difficile infection.
-
Extended-pulsed Dosing of Fidaxomicin vs. Standard-dose Vancomycin for Clostridium difficile Infection
A randomized, controlled, open-label clinical trial conducted at 86 European hospitals that included adults aged 60 years or older found that extended-pulsed dosing of fidaxomicin was superior to standard-dose vancomycin for sustained cure of Clostridium difficile infection and resulted in fewer disease recurrences.